keyword
MENU ▼
Read by QxMD icon Read
search

NALTREXONE OBESITY

keyword
https://www.readbyqxmd.com/read/27813192/naltrexone-changes-the-expression-of-lipid-metabolism-related-proteins-in-the-endoplasmic-reticulum-er-stress-induced-hepatic-steatosis-in-mice
#1
Azam Moslehi, Fatemeh Nabavizadeh, Ali Zekri, Fatemeh Amiri
Endoplasmic reticulum (ER) stress is closely associated with several chronic diseases such as obesity, atherosclerosis, type 2 diabetes, and hepatic steatosis. Steatosis in hepatocytes may also lead to disorders such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), fibrosis, and possibly cirrhosis. Opioid peptides are involved in triglyceride and cholesterol dysregulation. Naltrexone also attenuates ER stress induced hepatic steatosis in mice. In this study, we evaluated the effects of naltrexone on the expression of lipid metabolism-related nuclear factors and enzymes in the ER stress induced hepatic steatosis...
November 4, 2016: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/27773782/obesity-current-and-potential-pharmacotherapeutics-and-targets
#2
REVIEW
Vidya Narayanaswami, Linda P Dwoskin
Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders. Pharmacotherapeutic strategies to treat obesity are urgently needed. Research over the past two decades has increased substantially our knowledge of central and peripheral mechanisms underlying homeostatic energy balance. Homeostatic mechanisms involve multiple components including neuronal circuits, some originating in hypothalamus and brain stem, as well as peripherally-derived satiety, hunger and adiposity signals that modulate neural activity and regulate eating behavior...
October 20, 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27732121/safety-assessment-of-combination-therapies-in-the-treatment-of-obesity-focus-on-naltrexone-bupropion-extended-release-and-phentermine-topiramate-extended-release
#3
Bruno Halpern, Marcio C Mancini
Few studies on combination therapies for the treatment of obesity had been conducted until recently, when two fixed-dose combinations, bupropion-naltrexone ER fixed-dose combination and phentermine-topiramate ER titrated-dose combinations were evaluated in clinical studies that ultimately led to FDA approval. Areas covered: In this review, we discuss safety concerns about both combinations, the rationale and history of combination therapies for obesity (including phentermine plus fenfluramine), and possible future new combinations...
October 12, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27718159/reward-induced-eating-therapeutic-approaches-to-addressing-food-cravings
#4
REVIEW
Candida J Rebello, Frank L Greenway
The homeostatic controls over eating are inextricably linked to the reward aspects of eating. The result is an integrated response that coordinates the internal milieu with the prevailing environment. Thus, appetite, which reflects a complex interaction among the external environment, behavioral profile, and subjective states as well as the storage and metabolism of energy, has an important role in the regulation of energy balance. In the prevailing food environment which offers an abundance of food choices it is likely that the motivation to consume from a wide range of delectable foods plays a greater role in contributing to overeating than in the past when the motivation to eat was largely governed by metabolic need...
November 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27700187/an-update-on-naltrexone-bupropion-extended-release-in-the-treatment-of-obesity
#5
Katherine H Saunders, Leon I Igel, Louis J Aronne
As the prevalence of obesity continues to increase, the need for effective long-term treatment strategies for the overweight and the obese is critical. Pharmacology fills a large treatment gap between behavioral therapy, which is insufficient for the majority of patients, and devices and surgery, which are available to only a subset of patients. Naltrexone HCl and bupropion HCl Extended-Release (naltrexone XR/bupropion XR) was approved by the Food and Drug Administration for chronic weight management in 2014...
October 4, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27659699/opioid-receptor-antagonism-increases-pain-and-decreases-pleasure-in-obese-and-non-obese-individuals
#6
Rebecca C Price, Nicolas V Christou, Steven B Backman, Laura Stone, Petra Schweinhardt
RATIONALE: Endogenous opioids inhibit nociceptive processing and promote the experience of pleasure. It has been proposed that pain and pleasure lie at opposite ends of an affective spectrum, but the relationship between pain and pleasure and the role of opioids in mediating this relationship has not been tested. OBJECTIVES: Here, we used obese individuals as a model of a dysfunctional opioid system to assess the role of the endogenous opioid peptide, beta-endorphin, on pain and pleasure sensitivity...
September 22, 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27583422/update-on-office-based-strategies-for-the-management-of-obesity
#7
Michael Erlandson, Laurie C Ivey, Katie Seikel
Obesity is a common condition that is associated with numerous medical problems such as cardiovascular disease, pulmonary disease, and diabetes mellitus. Primary care physicians have an important role in helping patients develop a successful weight loss plan to improve their overall health. Dietary strategies emphasizing reduced caloric intake, regardless of the nutrient composition, are important for weight loss. Behavioral interventions such as motivational interviewing and encouraging physical activity lead to additional weight loss when combined with dietary changes...
September 1, 2016: American Family Physician
https://www.readbyqxmd.com/read/27565106/answers-to-clinical-questions-in-the-primary-care-management-of-people-with-obesity-pharmacologic-management
#8
Ken Fujioka, Jill Braverman-Panza
The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat). Indicated for the treatment of patients with overweight (body mass index [BMI] ≥27 kg/m2 with ≥1 weight-related comorbidity) or obesity (BMI ≥30 kg/m2), these medications provide new opportunities to address this burgeoning health problem.
July 2016: Journal of Family Practice
https://www.readbyqxmd.com/read/27539178/cardiovascular-effects-of-the-new-weight-loss-agents
#9
REVIEW
Matthew H Vorsanger, Pritha Subramanyam, Howard S Weintraub, Steven H Lamm, James A Underberg, Eugenia Gianos, Ira J Goldberg, Arthur Z Schwartzbard
The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described...
August 23, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27320641/obesity-current-treatment-and-future-horizons
#10
Ziad Omran
Obesity is growing at an alarming rate with huge consequences on health and economy. The worldwide prevalence of obesity has nearly doubled in 30 years. Obesity causes many physiological dysfunctions that affect nearly every organ producing multiple morbidities. Despite these facts, there is still no clear, well-defined solution. Notwithstanding the devastating prevalence and consequences of obesity, today only five medicines, orlistat, lorcaserin, phentermine-toprimate, bupropion-naltrexone and liraglutide, are approved by the FDA for long-term treatment of obesity...
June 16, 2016: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/27299618/association-of-pharmacological-treatments-for-obesity-with-weight-loss-and-adverse-events-a-systematic-review-and-meta-analysis
#11
REVIEW
Rohan Khera, Mohammad Hassan Murad, Apoorva K Chandar, Parambir S Dulai, Zhen Wang, Larry J Prokop, Rohit Loomba, Michael Camilleri, Siddharth Singh
IMPORTANCE: Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited. OBJECTIVE: To compare weight loss and adverse events among drug treatments for obesity using a systematic review and network meta-analysis. DATA SOURCES: MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central from inception to March 23, 2016; clinical trial registries. STUDY SELECTION: Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year compared with another active agent or placebo...
June 14, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27236593/precision-obesity-treatments-including-pharmacogenetic-and-nutrigenetic-approaches
#12
REVIEW
Maite Solas, Fermin I Milagro, Diego Martínez-Urbistondo, Maria J Ramirez, J Alfredo Martínez
Five pharmaceutical strategies are currently approved by the US FDA for the treatment of obesity: orlistat, lorcaserin, liraglutide, phentermine/topiramate, and bupropion/naltrexone. The most effective treatment seems to be the combined administration of phentermine/topiramate followed by lorcaserin and bupropion/naltrexone. In relation to the management of excessive weight, other aspects also need to be considered, including comorbidities accompanying obesity, drug interactions, and the risk of negative collateral effects, as well as individualized treatments based on the genetic make-up...
July 2016: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/27217728/naltrexone-hci-bupropion-hci-for-chronic-weight-management-in-obese-adults-patient-selection-and-perspectives
#13
REVIEW
Cenk Tek
Naltrexone, an opiate antagonist, and bupropion, a noradrenergic/dopaminergic antidepressant, have many effects on the reward systems of the brain. These medications impact eating behavior, presumably via their impact on food reward. However, only bupropion induces weight loss in obese individuals, while naltrexone does not have any appreciable effect. The combination of 32 mg of naltrexone and 360 mg of bupropion in a sustained-release combination pill form has been recently approved for obesity treatment...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27199749/stimulants-for-the-control-of-hedonic-appetite
#14
Alison S Poulton, Emily J Hibbert, Bernard L Champion, Ralph K H Nanan
The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behavior. Stimulant medications address both reward deficiency and enhance motivation, as well as suppressing appetite. They have long been recognized to be effective for treating obesity. However, stimulants can be abused for their euphoric effect...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27181165/pharmacologic-approaches-to-weight-management-recent-gains-and-shortfalls-in-combating-obesity
#15
REVIEW
Katherine H Saunders, Rekha B Kumar, Leon I Igel, Louis J Aronne
Obesity is a growing epidemic in the USA with over one third of adults presently classified as obese. Obesity-related comorbidities include many leading causes of preventable death such as heart disease, stroke, type 2 diabetes, and certain types of cancer. Modest weight loss of 5-10 % of body weight is sufficient to produce clinically relevant improvements in cardiovascular disease risk factors among patients with overweight and obesity. Until recently, there were limited pharmacologic options approved by the Food and Drug Administration to treat obesity...
July 2016: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/27114740/effectiveness-tolerability-and-practical-application-of-the-newer-generation-anti-obesity-medications
#16
REVIEW
Jeffrey S MacDaniels, Thomas L Schwartz
OBJECTIVE: Comparison of the efficacy and tolerability of five newer anti-obesity medications to guide clinical decision making, examining bupropion-naltrexone combination, liraglutide, lorcaserin, orlistat, and phentermine-topiramate combination. METHODS: A brief literature review and internet search for high-powered, randomized and placebo-controlled drug trials was conducted. Drug trial information was established for five currently approved anti-obesity medications...
2016: Drugs in Context
https://www.readbyqxmd.com/read/27063550/regulation-of-food-intake-and-the-development-of-anti-obesity-drugs
#17
Yue Chen
As the most significant cause of death worldwide, obesity has become one of the world's most important public health problems, but approved anti-obesity drugs are extremely limited. This article summarizes the feeding control circuits and regulators involved in obesity development, highlight the hypothalamus, melanocortin system and brain-gut peptide actions in this process, and the five US FDA approved anti-obesity medications in long term use, namely phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide and orlistat...
2016: Drug Discoveries & Therapeutics
https://www.readbyqxmd.com/read/27053517/drugs-to-treat-obesity-do-they-work
#18
REVIEW
Sarah Kim
Obesity is a disease that has historically eluded effective medical therapy. Prior to 2012, phentermine and orlistat were the only medications available to treat obesity in the USA, with phentermine approved only for short-term use. However, as of 2015, the repertoire of pharmacological agents available to treat obesity has greatly expanded to include four new drugs: lorcaserin, phentermine/topiramate extended release (ER), naltrexone ER/wellbutrin ER and liraglutide. Each has a unique mechanism of action and all are intended for long-term use...
July 2016: Postgraduate Medical Journal
https://www.readbyqxmd.com/read/26957883/naltrexone-bupropion-er-contrave-newly-approved-treatment-option-for-chronic-weight-management-in-obese-adults
#19
Matthew M Sherman, Sinziana Ungureanu, Jose A Rey
Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.
March 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/26954413/time-to-event-analysis
#20
COMMENT
Juliana Tolles, Roger J Lewis
No abstract text is available yet for this article.
March 8, 2016: JAMA: the Journal of the American Medical Association
keyword
keyword
108561
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"